Inspired by photovoltaic cells, the technology could also be used for neuromodulation and treating diseases like Parkinson’s.
Using two layers of P-type silicon, researchers made an ultra thin membrane that converts light into electric charges to adjust the heart’s beat.
The team found that administering an HDAC inhibitor orally effectively halted sperm production and fertility in mice while preserving the sex drive.
Researchers are grappling with the challenge of developing effective male contraceptives as existing attempts to block sperm production, maturation, or fertilization have fallen short, either offering incomplete protection or leading to severe side effects.
Now, a team of researchers at the Salk Institute in the US has developed a novel approach to halting sperm production, which is both non-hormonal and reversible, marking a significant advancement in male contraception research.
Researchers have identified a novel protein complex governing gene expression in sperm production. By administering an existing class of drugs, called HDAC (histone deacetylase) inhibitors to male mice, they effectively disrupt this complex, leading to infertility without impacting libido. This breakthrough suggests a promising avenue for non-hormonal and reversible male contraception, according to the team.
Imagine an army of self-propelling, radioisotope-covered particles 2,500 to 10,000 times smaller than a speck of dust that, upon injection into the body, search for and attach themselves to cancerous tumours, destroying them. Sounds like science fiction? Not so for mice with bladder cancer.
Researchers in Spain report that nanoparticles containing radioactive iodine and which propel themselves upon reaction with urea have the ability to distinguish cancerous bladder tumours from healthy tissue. These “nanobots” penetrate the tumour’s extracellular matrix and accumulate within it, enabling the radionuclide therapy to reach its precise target. In a study conducted at the Institute for Bioengineering of Catalonia (IBEC) in Barcelona, mice receiving a single dose of this treatment had a 90% reduction in the size of bladder tumours compared with untreated animals.
This novel approach may one day revolutionize the treatment of bladder cancer. Bladder cancer is the tenth most common cancer in the world, with over 600,000 new cases diagnosed in 2022 and more than 220,000 deaths globally, according to the World Health Organization’s Global Cancer Observatory.
Australian researchers have worked out how to fix a defect that causes lupus, and hope their world-first discovery will offer effective long-term treatment.
Published in Nature Communications, the Monash University-led study found a way to reprogram the defective cells of lupus patients with protective molecules from healthy people.
Using human cells, the new treatment restores the protective side of the immune system that prevents autoimmunity, which is when the immune system attacks its own cells.
Types of treatment for gallbladder cancer include surgery, radiation, and chemotherapy. Treatment of gallbladder cancer that has spread to other parts of the body, cannot be removed by surgery, or has come back after treatment is often within a clinical trial. Find out about treatment options for gallbladder cancer.
A UC Davis Health study found that a single dose of Bacillus Calmette-Guérin (BCG), the vaccine for tuberculosis (TB), reduced liver tumor burden and extended the survival of mice with liver cancer. The study, published in Advanced Science, is the first to show the promising effects of the vaccine in treating liver cancer.
Hepatocellular carcinoma (HCC) is the most common type of liver cancer. It is also the third leading cause of cancer-related deaths worldwide. Current therapies include surgery, radiotherapy, chemotherapy, immunotherapy and liver transplant. Yet, the therapy outcomes for liver cancer remain bleak.
BCG, the century-old TB vaccine, is derived from the live bacteria Mycobacterium bovis. It is considered safe and widely used around the world.